Evolent Health (EVH) Tops Q4 EPS by 6c; offers guidance

Evolent Health (NYSE: EVH) reported Q4 EPS of $0.23, $0.06 better than the analyst estimate of $0.17. Revenue for the quarter came in at $556.06 million versus the consensus estimate of $542.45 million.

GUIDANCE:

Evolent Health sees Q1 2024 revenue of $595-610 million, versus the consensus of $551 million.

Evolent Health sees FY2024 revenue of $2.4-2.5 billion, versus the consensus of $2.324 billion.

For earnings history and earnings-related data on Evolent Health (EVH) click here.

You May Also Be Interested In

• Apogee Enterprises (APOG) Tops Q1 EPS by 16c, Beats on Revenue; Offers FY27 Guidance
• KeyBanc lowers Nike rating to Sector Weight on near-term uncertainty
• Is AI momentum starting to cool? BofA weighs in